Gut microbiome effects on cardiometabolic disease through metabolism-modifying metabolites (Gut-MMM)
Evidence indicates that the bacterial flora in the human gastrointestinal tract substantially influences metabolism and development of cardiometabolic diseases. Nevertheless, the extent to which these factors are linked and whether pharmaceuticals can be developed on this basis are currently unclear. The underlying hypothesis of the project is that microbially synthesized molecules do not simply play a role as the body’s energy metabolizers and building blocks; they also play an important role as signal molecules that interact with receptors in endocrine organs.
- University of Copenhagen (Academic, Denmark)
- University of Amsterdam (Academic, Netherlands)
This page is only available in english
- Novo Nordisk Fonden (Non Profit, Denmark)